Randomized phase II study of nimotuzumab, an anti-EGFR antibody, plus irinotecan in patients with 5-fluorouracil-based regimen-refractory advanced or recurrent gastric cancer in Korea and Japan: Preliminary results.

@article{Kim2011RandomizedPI,
  title={Randomized phase II study of nimotuzumab, an anti-EGFR antibody, plus irinotecan in patients with 5-fluorouracil-based regimen-refractory advanced or recurrent gastric cancer in Korea and Japan: Preliminary results.},
  author={Yong-hwan Kim and Yasutsuna Sasaki and Kwang Hyun Lee and Sun Young Rha and S H Park and Narikazu Boku and Yoshito Komatsu and Taeseob Kim and S Kim and Yuh Sakata},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 4_suppl},
  pages={87}
}
87 Background: Nimotuzumab is a humanized IgG1 anti-EGFR monoclonal antibody. In previous studies, nimotuzumab has demonstrated efficacy associated with an absence of severe skin toxicity, commonly caused by other EGFR-targeting therapies. METHODS This is a Korea and Japan collaborative, multi-center, randomized, open-label study of nimotuzumab (400 mg, IV q1 week) plus irinotecan (150 mg/m2 IV q2 weeks) (N+I) versus irinotecan (I) in patients with advanced or metastatic gastric cancer… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 18 CITATIONS

Similar Papers

Loading similar papers…